Published in Amyloid on September 10, 2014
A 70-Year-Old Man With Large Cervical and Mediastinal Lymphadenopathies. Chest (2015) 0.92
Localized lymph node light chain amyloidosis. Case Rep Hematol (2015) 0.75
Primary Laryngo-tracheobronchial Amyloidosis: An Unusual Cause of Hoarseness and Dyspnea. Chin Med J (Engl) (2016) 0.75
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med (2004) 4.05
The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest (2006) 3.49
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood (2006) 2.97
Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol (2011) 2.82
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood (2011) 2.82
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood (2011) 2.72
Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A (2010) 2.41
Jade-1 inhibits Wnt signalling by ubiquitylating beta-catenin and mediates Wnt pathway inhibition by pVHL. Nat Cell Biol (2008) 2.34
Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol (2002) 2.26
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood (2009) 2.19
Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med (2007) 2.17
T1alpha, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolus formation at birth. Dev Biol (2003) 1.89
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood (2007) 1.83
Direct identification of PTEN phosphorylation sites. FEBS Lett (2002) 1.80
Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma (2003) 1.69
Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis (2013) 1.68
Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest (2003) 1.68
Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood (2011) 1.64
Oral non-Hodgkin's lymphoma: review of the literature and World Health Organization classification with reference to 40 cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2007) 1.62
The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol Cell Biol (2007) 1.52
CK2 phosphorylation of the armadillo repeat region of beta-catenin potentiates Wnt signaling. J Biol Chem (2003) 1.51
Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res (2005) 1.50
Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res (2002) 1.49
Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene (2002) 1.43
Inducible IkappaB kinase/IkappaB kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappaB activation in breast cancer cells. Cancer Res (2005) 1.41
Transthyretin (TTR) cardiac amyloidosis. Circulation (2012) 1.40
Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood (2004) 1.38
Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol (2003) 1.36
Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene (2002) 1.34
Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicol Pathol (2005) 1.34
RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland. Mol Cell Biol (2005) 1.32
A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biol Chem (2006) 1.26
B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum (2007) 1.24
New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation. J Clin Oncol (2013) 1.23
Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J (2009) 1.20
Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum (2007) 1.20
Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica (2012) 1.19
Immunoglobulin light chain amyloidosis. Expert Rev Hematol (2013) 1.15
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics (2008) 1.14
Primary intramedullary histiocytic sarcoma. World Neurosurg (2011) 1.13
Protein kinase CK2 is required for dorsal axis formation in Xenopus embryos. Dev Biol (2004) 1.08
Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol (2013) 1.06
The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain. Biochemistry (2010) 1.05
Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure. Transplantation (2010) 1.04
Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype. Cancer Res (2007) 1.02
Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica (2012) 1.00
MicroRNA 4423 is a primate-specific regulator of airway epithelial cell differentiation and lung carcinogenesis. Proc Natl Acad Sci U S A (2013) 1.00
An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid (2007) 1.00
Update on treatment of light chain amyloidosis. Haematologica (2014) 1.00
Cardiac nonamyloidotic immunoglobulin deposition disease. Mod Pathol (2006) 1.00
Loss of AND-34/BCAR3 expression in mice results in rupture of the adult lens. Mol Vis (2009) 0.97
V122I transthyretin variant in elderly black Americans. N Engl J Med (2015) 0.97
Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils. J Biol Chem (2010) 0.97
Evidence for a functional role of the molecular chaperone clusterin in amyloidotic cardiomyopathy. Am J Pathol (2010) 0.97
Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. Kidney Int (2003) 0.94
A new lysozyme tyr54asn mutation causing amyloidosis in a family of Swedish ancestry with gastrointestinal symptoms. Amyloid (2012) 0.94
Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5. Cancer Res (2012) 0.94
AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes. Am J Hematol (2006) 0.94
The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood (2003) 0.94
Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. Amyloid (2005) 0.93
Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains. Biochemistry (2007) 0.93
Increases in B-type natriuretic peptide (BNP) during treatment with lenalidomide in AL amyloidosis. Blood (2010) 0.91
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol (2013) 0.91
Diaphragm paralysis in primary systemic amyloidosis. Amyloid (2005) 0.90
Impaired 3',5'-cyclic adenosine monophosphate-mediated signaling in immediate early responsive gene X-1-deficient vascular smooth muscle cells. Hypertension (2010) 0.90
Localized amyloidosis of the breast: a case series. Amyloid (2011) 0.90
Threonine 393 of beta-catenin regulates interaction with Axin. J Cell Biochem (2009) 0.89
Detection of impaired homologous recombination repair in NSCLC cells and tissues. J Thorac Oncol (2013) 0.89
A solitary mediastinal mass due to localized AL amyloidosis: case report and review of the literature. Amyloid (2013) 0.89
Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis. Stem Cell Reports (2013) 0.89